GoodRx Forecasts Q2 Revenue Of ~$200M Versus Consensus Of $199.57M, With Adjusted EBITDA Margin In Low Thirty-Percent Range
Portfolio Pulse from Benzinga Newsdesk
GoodRx has projected its Q2 revenue to be around $200 million, slightly above the consensus estimate of $199.57 million. The company also expects its adjusted EBITDA margin to be in the low thirty-percent range.
May 09, 2024 | 10:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GoodRx forecasts Q2 revenue of approximately $200 million, surpassing the consensus estimate of $199.57 million, with an adjusted EBITDA margin in the low thirty-percent range.
GoodRx's projection of its Q2 revenue to be slightly above consensus estimates and its expectation of a healthy adjusted EBITDA margin are positive indicators for the company's financial health and operational efficiency. This news is likely to be viewed positively by investors, potentially leading to an increase in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100